Revolutionary Technology

Revolutionary Technology

The Staccato system enables rapid onset of action for many drugs.

Simple and Intuitive

Simple and Intuitive

The Staccato system is breath actuated, and a patient simply inhales to administer the drug dose.

Fast-Acting, Non-Invasive Treatment

Fast-Acting, Non-Invasive Treatment

Unlike injections, the Staccato system is noninvasive and does not require caregiver assistance.

Improved Patient Therapy

Improved Patient Therapy

Products for the treatment of acute and intermittent conditions.

Products with Unique Therapeutic Effect

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.

See Staccato® in action

Product Pipeline

We have already demonstrated that more than 200 FDA-approved compounds are feasible for delivery by the Staccato® system. Currently we have six development programs focused on five acute and intermittent conditions.

More about our Products

Recent News

  • July 24, 2008
    Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

  • July 9, 2008
    Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

  • June 23, 2008
    Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual...

Noteworthy

Building a Pharmaceutical Company.
56 page PDF (800k)

Download the report
View other reports & filings

Building a Commercial Infrastructure

As our development pipeline grows and our clinical candidates advance in the development process, we have begun building a commercial infrastructure to support what we hope will be a growing portfolio of approved pharmaceutical products.

More on Our Growing Business